MARKET

ARAY

ARAY

Accuray
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.730
+0.230
+6.57%
After Hours: 3.770 +0.04 +1.07% 17:49 09/17 EDT
OPEN
3.520
PREV CLOSE
3.500
HIGH
3.790
LOW
3.470
VOLUME
3.03M
TURNOVER
--
52 WEEK HIGH
6.02
52 WEEK LOW
2.220
MARKET CAP
338.79M
P/E (TTM)
-53.6691
1D
5D
1M
3M
1Y
5Y
3 Medical Equipment Stocks Under $10 to Buy Now
StockNews.com · 23h ago
Accuray's (ARAY) CyberKnife Favored For Prostate Cancer Treatment
Per the PACE trial data, patients treated with Accuray's (ARAY) CyberKnife SBRT are likely to experience lesser bladder-related side effects unlike conventional linear accelerator.
Zacks · 2d ago
NNVC, LIFE and DATS pre market gainers
Communications Systems JCS +27% declares $3.50 special dividend NanoViricides (NYSE:NNVC) +21% completes licensing for Coronavirus field which includes current COVID-19 drug development aTyr Pharma (NASDAQ:LIFE) +13%. DatChat (NASDAQ:DATS) +10%. SeaChange ...
Seekingalpha · 3d ago
BRIEF-Accuray Says Cyberknife Robotic Radiotherapy Platform Is Superior To Conventional Linear Accelerators
reuters.com · 3d ago
Accuray Says Data From PACE Trial Indicate CyberKnife Is 'Superior to Conventional Linear Accelerators in Reducing Incidence of Bladder Side Effects in Prostate Cancer Patients'
Accuray Incorporated (NASDAQ:ARAY) announced today that data from the PACE – Prostate Advances in Comparative Evidence – trial indicate the company's CyberKnife® robotic radiotherapy
Benzinga · 3d ago
Accuray CyberKnife® Robotic Radiotherapy Platform is Superior to Conventional Linear Accelerators in Reducing Incidence of Bladder Side Effects in Prostate Cancer Patients
Accuray Incorporated (NASDAQ: ARAY) announced today that data from the PACE – Prostate Advances in Comparative Evidence – trial indicate the company's CyberKnife® robotic radiotherapy platform is superior to conventional linear accelerators in reducing the...
PR Newswire · 3d ago
Why Is Accuray (ARAY) Down 3.4% Since Last Earnings Report?
Zacks.com · 09/10 15:30
Update: Ooma Q2 Tops Street Estimates; Names Hamamatsu as Chief Financial Officer -- Shares Advance 12%
MT Newswires · 09/03 14:18
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARAY. Analyze the recent business situations of Accuray through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARAY stock price target is 8.20 with a high estimate of 10.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 182
Institutional Holdings: 74.61M
% Owned: 82.14%
Shares Outstanding: 90.83M
TypeInstitutionsShares
Increased
48
3.91M
New
16
2.15M
Decreased
44
3.45M
Sold Out
21
1.13M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+1.54%
Healthcare Equipment & Supplies
+0.65%
Key Executives
President
Suzanne Winter
Chief Executive Officer/Director
Joshua Levine
Chief Financial Officer/Vice President/Controller
Brandy Green
Senior Vice President/Chief Administrative Officer
Patrick Spine
Senior Vice President/General Counsel/Secretary
Jesse Chew
Senior Vice President
Jim Dennison
Director
Mika Nishimura
Director
Byron Scott
Independent Director
Elizabeth Davila
Independent Director
James Hindman
Independent Director
Beverly Huss
Independent Director
Anne Le Grand
Independent Director
Richard Pettingill
Independent Director
Joseph Whitters
No Data
About ARAY
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

Webull offers kinds of Accuray Incorporated stock information, including NASDAQ:ARAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARAY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARAY stock methods without spending real money on the virtual paper trading platform.